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Endocrine disrupting chemicals (EDCs) are substances that alter the function
of the endocrine system and consequently cause adverse effects to humans
or wildlife. The release of particular EDCs into the environment has been
shown to negatively affect certain wildlife populations and has led to restric-
tions on the use of some EDCs. Current chemical regulations aim to balance
the industrial, agricultural and/or pharmaceutical benefits of using these
substances with their demonstrated or potential harm to human health or
the environment. A summary is provided of the natural science evidence
base informing the regulation of chemicals released into the environment
that may have endocrine disrupting effects on wildlife. This summary is
in a format (a ‘restatement’) intended to be policy-neutral and accessible
to informed, but not expert, policy-makers and stakeholders.1. Introduction
The endocrine system plays a critical role in almost all biological and physio-
logical functions. Endocrine disrupting chemicals (EDCs) are substances (or
mixtures of substances) that alter the function of the endocrine system and conse-
quently are capable of causing adverse effects to humans or wildlife [1]. EDCs
include compounds with important agricultural, industrial and pharmaceutical
uses, which can become pollution problems through inadvertent human or wild-
life exposure. Many different types of chemicals can be EDCs and, beyond their
effects on the endocrine system, there is no single characteristic or property that
they all share. Particular compounds may affect other biological processes
in addition to their EDC effects. Some common natural substances may have
endocrine effects (for example sugar and caffeine) but concern about EDCs in
the environment chiefly focuses on synthetic chemicals that can sometimes be
active at low or even very low concentrations. Though not unique to EDCs, the
ability of some chemicals to be biologically active at very low concentrations
raises particular regulatory issues. Timing of exposure is also critical, because
EDCs may only have an effect at particular life-history stages. Many of the first
EDCs to attract regulatory attention had long half-lives in the environment and
became concentrated in certain species ofwildlife, negatively affecting their popu-
lation viability. More recently, and in addition, there has been concern about




2though short-lived, are commonly found in the environment
due, for example, to their continuous release in wastewater.
The aim of the project described here is to provide a ‘resta-
tement’ of the natural science evidence base relevant to the
design and implementation of EDC regulations to protect
wildlife. We define wildlife as all non-domesticated animals,
including amphibians, fish and invertebrates as well as birds,
reptiles and mammals. Humans are also exposed to these
chemicals when, for example, they use products containing
EDCs or through contamination of food (for an introduction
to EDCs and human toxicology see [1] or [2]). Toxicology
studies for human health protection may anticipate issues for
wildlife and vice versa.
Some of the most well-documented examples of wildlife
population reductions caused by industrial and agricultural
chemicals were due to the endocrine disrupting properties of
those chemicals. The widespread use of the organochlorine
insecticide DDT from the 1950s onwards was a major driver
of declines in birds of prey because of reproductive failure
due to eggshell thinning [3,4]. The use of polychlorinated biphe-
nyls (PCBs) in electrical equipment and for other industrial
purposes resulted in large quantities of these highly persistent
chemicals entering the environment. They have become concen-
trated in the bodies of species at the top of ecological foodwebs,
particularly in high-latitude regions of the Northern Hemi-
sphere, and are linked to impaired reproduction [5,6]. Use of
both types of compounds is now restricted worldwide. Not
all the toxic effects of these chemicals are through endocrine dis-
ruption, but the association of EDCs with a number of classic
cases of pollution affecting wildlife means that they attract par-
ticular attention from environmental protection agencies, and
raise strong concerns for non-governmental organizations
involved in environmental protection.
We have attempted to write this restatement in a succinct
manner comprehensible to non-expert but informed readers
while providing an entry into the technical literature. We
have tried to be policy-neutral, though we realize that this
can never be absolute. In a short summary of a very large sub-
ject it is impossible to survey all of the literature relevant to the
environmental effects of the very many types of EDCs. While
our review is inevitably selective, we have tried to emphasize
what, in the judgement of the authors, are the generic issues
of relevance to multiple EDCs.2. Methods
This evidence summary was produced using a similar procedure
to that used in previous restatements (e.g. [7,8]). The literature on
EDCs and wildlife was reviewed and a first draft produced by a
subset of the authors. At a workshop, all authors discussed
and assessed the different evidence components in the light of
the strength and quality of the available literature. Subsequently,
using a restricted set of terms (see Appendix A, } 3), each piece
of evidence was assigned a code with our assessment of the
nature of the evidence base.
A revised evidence summary was produced and further
debated electronically to produce a consensus draft. The restate-
ment was then sent to 28 stakeholders or stakeholder groups,
including scientists involved in environmental pollution research,
representatives of the pharmaceutical, water and chemical
industries and non-governmental organizations concerned with
environment and conservation, and UK government departments
and statutory bodies responsible for environmental chemicals. We
asked them to judgewhether the literature had been fairly coveredand that we had not inadvertently overlooked key evidence, and to
review the evidence codes outlined above. We also asked the sta-
keholders to comment on whether the restatement achieved its
aims of being policy-neutral and not a work of advocacy. The
document was revised in the light of much helpful feedback.
Though many groups were consulted, the project was conducted
completely independently of any stakeholder and was funded by
the Oxford Martin School (part of the University of Oxford).3. Results
The summary of the natural science evidence base relevant
to policy-making on EDCs and wildlife is given in Appendix
A, with an annotated bibliography (which includes a
glossary of technical terms) provided as electronic
supplementary material.4. Discussion
In this restatement, we have used the World Health Organiz-
ation (WHO) definition (see Appendix A, } 4) of an EDC.
This is probably the most commonly employed, though not
without issues. For example, as noted above, some substances
cause adverse effects but at concentrations that would
seldom, if ever, occur in the field. The WHO definition
would include them in this category, but the many everyday
chemicals involved are not typically considered EDCs.
Even if a chemical is shown to have endocrine disrup-
tive activity on wildlife by the WHO definition, the chief
issue for regulators is whether the substance causes harm at
the population and ecological community levels. This is often
challenging to determine as there are few or no baseline popu-
lation data available for most species, and typically we have
a poor understanding of how different factors affecting
mortality and fecundity combine to influence population
abundance and resilience.
If an adverse effect is observed in wildlife, determining
its cause and identifying any association with a particular
chemical compound can be extremely difficult. In almost all
cases where an EDC (or mixture of EDCs) has caused adverse
effects on wildlife, the connection with exposure to the EDC(s)
has been established only after the wildlife population had
declined. Improved prediction of which compounds may
cause harm when released into the environment would be
very helpful. One challenge is to understand how different
EDCs combine to affect wildlife. At the moment the potential
and actual effects of EDCs (and other chemicals) are generally
evaluated on an individual basis, while wildlife populations
are exposed to complex cocktails of compounds that can
interact with each other [9].
Finally, we note a number of limitations of this study and
discuss how it might be extended.
First, we are aware that in attempting to discuss EDCs
as a category of chemicals wewere unable to provide a detailed
evidence summary of all the work relevant to every EDC, due
to the numbers and varieties of substances involved. The
rationale behind our approach was to discuss common issues
relevant tomanyEDCs, aswell as to learn lessons fromparticu-
lar types of chemicals that have been shown to be harmful to
wildlife and have thus been banned or their use severely
restricted. Restatements for specific EDCs in which the litera-
ture is more comprehensively surveyed could be produced




3neonicotinoid insecticides [7,10] are examples of more targeted
studies (involving pollutants that are not EDCs) where a
greater coverage of the literature was possible.
The second limitation to our study is that we have focused
only on the effects of EDCs onwildlife and not on humans. The
reason for this is that the two issues are somewhat different.
Society has a very low tolerance of harm done to individual
humans, while for wildlife the impacts on populations are typi-
cally considered most important. Sources and pathways of
exposure to humans and wildlife may also be different. Never-
theless, as we discuss in the restatement, the two topics are
related, and bringing them together in the future in the context
of the ‘One Health’ [11] agenda may be valuable.
Finally, the restatement focuses on the natural science evi-
dence base relevant to the regulation of EDCs. Policy-makers
seeking to shape regulatory regimes will also require evidence
about the economic costs and benefits of different interven-
tions, as well as their political and social acceptability.
Performing economic cost-benefit analyses in this area is com-
plicated because of the need to include not only the direct
financial impact of regulation (or lack thereof) on industry,
consumers and government, but also the direct and indirect
economic consequences of the effects of EDCs on human
health and the state of the environment. There are also other
topics in the social sciences and humanities, including the his-
tory and political economy of regulating pollutants in the
environment, where research may be valuable to policy-
makers in understanding the desirability and acceptability of
different modes of chemical regulation to society [12].
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(A) Introduction and aims
1. Endocrine disrupting chemicals (EDCs) are substances that
alter the function of the endocrine (hormone) system of
humans and animals, leading to adverse effects on individ-
uals or populations. Some EDCs, singly or as mixtures, can
cause negative effects at very low concentrations andinclude pollutants that have been shown to severely
harm various species of wildlife.
2. The restatement aims to summarize the science evidence
base contributing to the development of policy on the
impact of EDCs on wildlife. Effects on human health are
not covered. It does not attempt to survey comprehen-
sively all evidence relating to every class of EDC, but
highlights key generic issues of relevance to policymakers.
3. An assessment by the authors of the nature of the different
evidence components is provided. We use the following
descriptions, which explicitly are not a ranking, indicated
by abbreviated codes.
— [B] Background material, for example describing basic
chemistry, legislation etc.
— [S] Strongly supported by a substantial evidence base
where further information is unlikely to change the
current consensus.
— [L] Less strongly supported by the existing evidence
base and where further information might alter the
current consensus.
— [E] Expert opinion based on information from related
substances or general principles from different fields
of science.
(B) What endocrine disrupting chemicals are
This section defines EDCs and gives some examples of better-
studied classes, though without providing a comprehensive
catalogue.
4. We follow the World Health Organization (WHO), which
defines an EDC as ‘an exogenous substance or mixture that
alters function(s) of the endocrine system and consequently
causes adverse health effects in an intact organism, or its
progeny, or (sub) populations’ [B].
a. The endocrine system is made up of the glands and
other tissues that secrete hormones: molecules that
transmit information within the body [B].
b. Hormones can be biologically active at very low concen-
trations, often in the parts per trillion (ppt, 10212) to
parts per billion (ppb, 1029) range [B].
c. TheWHO definition applies to both human and wildlife.
It implies that for a substance to be an EDC, it must have
an adverse effect on the organism. The demonstration
that a chemical alters endocrine function is not enough
without harm being demonstrated (other definitions do
not have this requirement). Whether harm to the individ-
ual affects population viability is a critical question in
assessing the ecological effects of EDCs [B].
d. The WHO refers to substances that possess properties
that might be expected to lead to endocrine disruption
in an intact organism, its progeny or (sub)populations
as ‘potential EDCs’ [B]. The European Food Safety Auth-
ority (EFSA) refers to substances that interact or interfere
with the endocrine system, but do not lead to adverse
effects, as ‘endocrine active substances’ [B].
e. Adverse effects are defined as a ‘change in the mor-
phology, physiology, growth, development, reproduction
or lifespan of an organism that results in an impairment
of functional capacity, an impairment of the capacity
to compensate for additional stress or an increase in




45. There is uncertainty about the fraction of synthetic chemi-
cals entering the environment that are EDCs. Over 140 000
compounds have been registered under the EU regulation
Registration, Evaluation, Authorisation and Restriction of
Chemicals (REACH), of which roughly 30 000 are in
common use. Most of these have not been tested for endo-
crine disrupting effects in the laboratory, and fewer have
been investigated in vivo. The number of chemicals so far
found or suspected to have ED effects is 800–1000 [L].
a. High-throughput laboratory screens are available to test
large numbers of compounds for evidence of endocrine
activity (for example the US Environment Protection
Agency’s Tox21 programmehas assessed over 10 000 com-
pounds in vitro for endocrine disrupting and other adverse
effects). While valuable as an initial screen, the assays can
produce false negatives and false positives and cannot
cover all the ways that EDCs may harm wildlife [L].
b. The degradation products and metabolites of EDCs may
also be EDCs. While their effects will be observed during
in vivo testing, these metabolic products are less fre-
quently subject to testing in vitro. Furthermore, in vitro
testing systems do not necessarily capture the processes
of metabolism that EDCs undergo in an intact organism.
Cases are known where secondary products are more
potent EDCs, or are present at higher concentrations in
the environment, than the parent molecule [S].
6. EDCs in the environment may be (or be derived from) mol-
ecules specifically used because of their effects on the
endocrine system in humans or wildlife (for example, cer-
tain steroid contraceptives, other pharmaceuticals and
some pest-control products) or theymay be used for comple-
tely different purposes with their EDC activity being
coincidental (examples include compounds used as plastici-
zers or flame retardants, and in personal care products) [B].
a. While most problematic EDCs are synthetic chemicals,
some are natural. For example, the thyroid disrupter
perchlorate (} 11.e) occurs in natural mineral deposits,
while phyto-oestrogens in plants (which may have
oestrogenic or anti-oestrogenic effects) can enter the
environment from pulp mill effluents (} 13.c) [B].
b. Some EDCs can also be classified ‘persistent organic
pollutants’ or POPs—highly stable, typically halo-
genated organic compounds with high lipid solubility.
Not all POPs are EDCs [S].
7. The potential threat to wildlife from EDCs became widely
accepted in the 1990s, leading to national or international
prohibition of some substances, though in a number of
cases harm was established and bans enacted before endo-
crine disruption was identified as the mode of action.
Continuing problems result from the persistence of these
substances in the environment or their continued use in
some countries [B].
a. Tributyltin (TBT) was used widely in antifoulant boat
paints. Observations of masculinization and sterility of
gastropod molluscs in the 1970s, especially in marinas
and harbours, led to its identification as a potent mol-
lusc EDC (though initially its mode of action was
incorrectly identified) [S]. It persists in anaerobic (low
oxygen) marine sediments from which it can re-enter
the water body and harm molluscs [S]. National then
global bans (2008) have reduced amounts of TBT in
the environment to a level that has allowed many
marine mollusc populations to recover [S].b. DDT (Dichlorodiphenyltrichloroethane) is an organo-
chlorine insecticide that was used widely in agriculture
before bans were introduced in different countries from
the 1960s due to its persistence and impacts on both
human health and wildlife. Ornithologists observed
high incidences of egg shell breakage in nests of birds
of prey that were spatio-temporally correlated with
DDT use. Experiments (on other bird species) confirmed
that the DDT metabolites (DDE and DDD) reduced the
reproductive success of birds of prey through egg-shell
thinning, probably caused by endocrine disruption in
the shell-producing gland, though the precise mechan-
ism is still not clear [S]. A global ban was instituted in
2001, though restricted application in disease vector con-
trol is still permitted [B]. This has reduced levels of DDT
in the environment and has contributed to the recovery of
a number of bird of prey populations in Europe and
North America [S]; however, continuing high levels of
DDT in Ade´lie penguins are probably due to its recent
release from glacial meltwaters [E].
i. Many other organochlorine pesticides (for example
dieldrin, endosulfan and dicofol) were also restricted
globally or regionally and have subsequently been
shown to be EDCs [L, S]. An accidental spill of dico-
fol into a Florida lake was followed by declines in
alligator numbers that have been attributed to its
endocrine-mediated effects [L].
c. Polychlorinated biphenyls (PCBs) were used widely in
industry, particularly in the manufacture of electrical
equipment. They impair reproductive and other endo-
crine functions. From the late 1960s they were found to
be present at concentrations high enough to cause toxic
effects in many species of wildlife [S]. Concerns for wild-
life were raised when farmed mink feeding on Lake
Michigan coho salmon suffered reproductive failure due
to high levels of PCB in their food [S]. Very high PCB con-
centrations in Arctic predator and some cetacean and seal
populations in European waters have been correlated
with long-term population declines and low rates of
reproduction [S]. There are numerous types (congeners)
of PCBs which differ in their persistence and endocrine
properties. Regional and, from 2001, global bans were
introduced, subsequent decline of PCBs and other persist-
ent organic pollutants (e.g. DDT } 7b) have been linked to
improvements in reproductive success and higher popu-
lations of fish-eating vertebrates such as grey seals,
otters and fish eagles in northern Europe. However, as
they are highly persistent in the environment and
continue to pose a threat to some wildlife species.
i. For example, no orca calves have been observed in 25
years in a population from north-west Scotland and
west Ireland where levels of EDCs (in particular,
PCBs) are above the toxic equivalency factor (} 19.g.ii)
expected to have adverse effects, and higher than
those seen elsewhere in the world [S]. A recent model-
ling study predicts that 40% of global orca populations
face extinction in the next 100 years due to PCBs. Popu-
lations near sources of pollution and those which feed
higher in the food chain are most at risk [L].
8. Natural oestrogens and those used in human contraceptives
(which may be the same compounds found in humans
and other animals or synthetic molecules with similar




5environment via wastewater, the cumulative effect of
multiple substances (see } 19.g) and/or because they have
effects on wildlife at very low concentrations.
a. The effects on wildlife of both natural oestrogens (oes-
trone, E1; oestradiol, E2; and oestriol, E3), and synthetic
oestrogens (17a-ethinyl oestradiol, EE or EE2) used in
the contraceptive pill were first noticed in the 1980s
when feminized male fish were seen in rivers near
municipal wastewater outflows [S]. This observation
prompted experiments that demonstrated the presence
of oestrogens in the environment were the cause [S]
(also see } 24.a).
b. Comparison of rivers upstream and downstream of
wastewater treatment plants have frequently demon-
strated increased feminization (intersex) downstream
[S]. The degree to which this affects population densities
is not clear, and complicated to determine in species
stocked for angling [E]. Studies comparing fish popu-
lation density in rivers with and without wastewater
plants have not found differences, though determining
how different environmental factors affect fish abun-
dance is challenging [L].
i. There were no differences apparent in the effective
population size of roach living in five river catch-
ments with differing levels of wastewater effluent [L].
c. Livestock waste is a further source of oestrogens in the
environment [S]. The impacts are similar to those
caused by human-derived oestrogens from wastewater
treatment plants [S].
9. Many pharmaceuticals have endocrine effects. While these
have the potential to harm wildlife, their use is relatively
unrestricted because of their human health importance [B].
Some examples of high-volume pharmaceuticals include:
a. Metformin is extensively prescribed, primarily for Type
II diabetes; large amounts enter the environment via
municipal wastewater. One study has suggested that it
may act like a feminizing oestrogen in fish, but this is
not proven [L]. Use is expected to increase with the
growing incidence of Type II diabetes [E].
b. Use of anti-depressants is increasing. Fluoxetine (a selective
serotonin reuptake inhibitor [SSRI] marketed as Prozac) is
present in municipal wastewater and in the environment.
Possible effects on wildlife have been investigated, but it
is not yet clear whether typical concentrations are high
enough to cause adverse effects [L]. SSRIs mediate a
change in neurotransmitter balance with secondary effects
on the endocrine system, and there is debate as to whether
SSRIs should be considered EDCs [L].
c. Bicalutamide and cyproterone acetate are the most com-
monly prescribed anti-androgens for prostate cancer,
and so of potential concern as EDCs inwildlife.Modelling
of likely concentrations in UK rivers, and experimental
studies on fish, indicated that harm was unlikely to
occur at present rates of use [L].
d. The progestins are a class of drugs that have similar
effects to the hormone progesterone [B]. They are used
for contraception, in hormone replacement therapy
and as cancer drugs [B]. Individual progestins at con-
centrations similar to those predicted to occur in UK
rivers have been shown in laboratory experiments to
have adverse effects on fish and frog reproduction [S],
and it is likely that the effects of different types of
progestin will combine additively [E] (} 19.g).10. Veterinary pharmaceuticals used in agriculture, in par-
ticular those used in relatively large quantities for
economic reasons (for example, growth promotion)
rather than health reasons, may become environmental
EDCs (see also } 12.a) [S].
a. For example, trenbolone, an anabolic steroid used in
the USA and some other countries (banned in the
EU) to increase muscle growth in beef cattle, is
found in agricultural run-off at concentrations that
may affect fish and frog reproductive physiology [S].
11. A number of EDCs with the potential to affect wildlife
continue to be used in industry because the extent of
their harm is not certain or because of the lack of
economically viable, non-EDC substitutes [E].
a. Bisphenol A (BPA) is found in many plastic products
and enters the environment through wastewater and
product disposal [B]. There is evidence showing that
it can affect reproduction (due to its oestrogenic prop-
erties) [S] and that it can also affect neurodevelopment
(perhaps through perturbations of thyroid hormones)
[L]. BPA may have effects on some wildlife at concen-
trations regularly observed in the environment [E].
Human health concerns have led to some restrictions
(such as use in baby-feed bottles) and to its recent
classification as a substance of very high concern
(SVHC) under EU REACH (} 26) legislation [B].
b. Phthalates are plasticizers used to make plastics more
pliable and in personal care products. They are among
the most abundant man-made chemicals in the aquatic
environment, entering through municipal wastewater,
sewage sludge application and poor industrial waste
disposal [S]. Some phthalates are considered to be
risks to human health because of the effects on repro-
ductive and thyroid endocrine systems, and their use
in children’s toys is restricted in the EU and other juris-
dictions [B]. In the laboratory, some phthalates have
been shown to have endocrine effects in wildlife, but
at above environmentally relevant doses [L].
c. Polyfluoroalkyl and perfluoroalkyl substances (PFASs)
are used in a variety of industrial processes as well as
in fire-fighting foam. Some can affect reproductive and
growth endocrine systems, and their presence in
humans led to a ban on certain (‘long-chain’) forms.
While they are persistent and bioaccumulate (} 17)
[S], evidence about whether they cause harm is limited
[E]. Other (‘short-chain’) PFASs continue to be used in
industry [B].
d. Polybrominated diphenyl ethers (PBDEs) are used as
flame retardants in furnishings and electronics, and
can have adverse effects on thyroid hormone function
[S]. They are persistent and bioaccumulate (} 17) and
have been found in wildlife throughout the world,
and some types (the penta-, octa- and deca- forms)
are now banned under international conventions or
regional legislations [B].
e. Perchlorate is an oxidizing agent used in solid rocket
fuels and is also naturally present in some mineral
deposits mined as fertilizers [B]. It has been shown
to interfere with iodine uptake by the thyroid gland
in amphibians, leading to retardation of metamorpho-
sis and reduced growth rates. Thyroid disruption has
been demonstrated in some North American wildlife




6f. Nonylphenol is a breakdown product of alkylphenol
ethoxylates which are used in manufacturing as surfac-
tants [B]. Nonylphenol and other alkylphenols bind to
the oestrogen receptor and have been shown to cause
feminization in fish [S]. Nonylphenol ethoxylate has
been classified as a ‘priority hazardous substance’
under the EU Water Framework Directive (} 26.b)
and its use is restricted in the European Union. How-
ever, in other jurisdictions, particularly in industrial
areas, concentrations in rivers can be high enough
that negative effects on wildlife are very likely [E].
12. There is uncertainty about whether some substances that
are known to be harmful to wildlife should be classified
as EDCs. This is significant as some jurisdictions have
specific regulations governing EDC use.
a. Diclofenac is a non-steroidal anti-inflammatory drug
(NSAID) used in human and veterinary medicine
[B]. It was used to alleviate suffering in cattle in
India (where it is now banned). Severe declines
(greater than 95%) in vulture populations occurred
due to feeding on the carcasses of treated cattle [S].
Initially thought to be an EDC, diclofenac is now
known to cause visceral gout and kidney failure
through interfering with uric acid transport [S].
b. Atrazine is a herbicide used for agricultural weed con-
trol in many countries (it is no longer registered in
Europe due to concerns about ground water contami-
nation) and enters the environment via spray drift and
agricultural run-off [B]. There is some evidence atra-
zine may lead to feminization of amphibians (and
possibly other vertebrates) [L]. Atrazine may also
reduce amphibian metamorphosis success, an indi-
cation of thyroid hormone disruption [L]. The
evidence for the endocrine disruptive effects of atra-
zine under field conditions is highly contested and
politicized, with examples of failure to replicate results
and accusations of bias directed at both industry and
non-industry researchers [E].(C) How endocrine disrupting chemicals enter
and persist in the environment
This section describes how EDCs derived from human
activity enter the environment and their subsequent fate.
These pathways are largely shared with other non-EDC
pollutants.
13. EDCs can enter the environment from point and diffuse
sources. The former includes sites where treated and
untreated wastewater (via domestic, hospital and indus-
trial sources) is routinely discharged into rivers, waste
landfill sites, and incidences of accidental pollutant
release. The main diffuse sources are pesticide spray
drift and agricultural runoff containing agrichemicals
and compounds derived from animal manure. Use of
wastewater sludge on agricultural land can be a source
of EDCs derived from pharmaceuticals, personal care
products and household chemicals such as PBDEs
(} 11d) used as flame retardants [S].
a. Wastewater and landfill leachate contain many differ-
ent EDCs that vary in time and space [S].b. Commercial export of waste, in particular to countries
with weak environmental protection, can result in new
sources of EDCs entering the environment [S].
c. Pulp mill effluent contains a range of chemicals, and
its composition depends on the processes used and
tree species; many plant steroids are endocrine-active
substances [B]. Male-biased sex ratios, increases in
the expression of male secondary sexual character-
istics, changes in fish mating behaviour and
decreases in egg production have been found in var-
ious species of fish living downstream of pulp mills
or experimentally exposed to pulp mill effluent [S].
14. The level of dilution influences the effects of EDCs entering
the environment viawastewater discharge. Domesticwaste-
water can form a high fraction of flow where population
densities are high alongside rivers of modest dilution
capacity (for example as in much of the UK). Dilution is
greater in marine environments, though less so in harbours
and shallows seas compared with major oceans [S].
15. Once in the environment, some persistent EDCs (in
common with other pollutants) are volatilized and trans-
ported over long distances in the atmosphere before
redeposition, or are moved long distances by ocean
currents [S].
a. Persistent EDCs (and some other substances) tend to
accumulate at high latitudes because cold oceans
hold more dissolved gases, because biodegradation
rates are slower at low temperatures and because the
probability of re-volatilization into the atmosphere is
lower in cold regions [S].
16. EDCs (like other compounds) vary considerably in the rate
at which they are broken down in the environment [S]. The
half-life of EDCs such as natural oestrogens (} 8) is a few
days in the aquatic environment while TBT (} 7.a) and
some forms of PCBs (} 7.c) and other organochlorines
(} 7.b) can persist for decades in soils and sediments [S].
a. Concentrations of EDCs in the environment are a
dynamic balance between release and breakdown.
Persistent compounds break down slowly in the
environment but those with rapid turnover (for
example BPA [} 11.a] or the synthetic oestrogen EE2
[} 8]) may still occur at concentrations that may have
effects on wildlife if they are continuously released at
a sufficiently high rate (termed pseudopersistence) [B].
b. EDCs can be sequestered in parts of the environment
where breakdown or dilution is reduced (for example,
in sediments, glacial ice or the deep oceans) and then
released at a later time from what become secondary
sources of legacy pollutants.
c. EDCs used in industry and construction (in particular
PCBs [} 7.c] and fire retardants [} 11.d]) can enter the
environment later at the time of disposal or demolition
of thebuildings intowhich theyare incorporated (}31) [S].
17. EDCs vary in the degree to which they can persist in
animal bodies (as do non-EDC contaminants). Lipophilic
molecules (which associatewith fat) tend not to be excreted
and so can increase in concentration (bioaccumulation or
bioconcentration). Predators can acquire EDCs from their
prey and their concentrations often increase higher in the
food web (biomagnification). The two processes of bio-
accumulation and biomagnification explain the high
concentrations of some EDCs in long-lived apex predators




7a. Concentrations of persistent EDCs (e.g. PCBs } 7.c,
DDT } 7.b) tend to increase with age in many ver-
tebrate species and so can be particularly high in
long-lived individuals [S].
b. Due to biomagnification, the amount of PCBs (} 7.c) in
200–300 g of salmon flesh in Lake Ontario has been
estimated to be equivalent to that in ‘several million
litres of lake water’ [S].
c. In mammals, lipophilic EDCs can be transferred to
offspring during gestation and lactation. Marine
mammals have a very high milk fat percentage leading
to substantial lipophilic EDC transfer, particularly in
those species that have a relatively long lactation
period (for example, cetaceans and polar bears) [S].
(D) How we know if an endocrine disrupting
chemical is a problem in wildlife
This section describes how evidence is obtained about the
potential endocrine disrupting properties of different chemi-
cals in wildlife. The section begins with studies in the
laboratory and moves to information collected in the field.
18. Some substances used in industry and medicine are
identified as EDCs when tested for their potential toxicity
to human health. As endocrine pathways tend to be
highly conserved across different types of organisms
such studies are informative in identifying potential
threats to wildlife (termed read across). Permissible
human exposure levels are conservative, and bans and
restrictions to protect human health will indirectly benefit
wildlife [B].
a. Animals distantly related to humans and other ver-
tebrates, and which have very different physiologies,
may show unexpected effects not seen in vertebrate
toxicity screens. An example is the strong effect of
TBT (} 7.a) on reproduction in molluscs [S].
b. Read across refers to intrinsic risk and can be less
informative where wildlife and human exposure are
very different. For example, many EDCs occur at rela-
tively high concentrations in aquatic environments
where absorption across the epidermis or gills may
cause harm not anticipated by laboratory tests with
EDCs administered orally to terrestrial animals [B].
19. Laboratory experiments can be carried out to assess the
potential endocrine-mediated harm of varying concen-
trations of a chemical on different animal species
(in vivo) or in cell culture assays (in vitro testing). The
experimenter may measure change in hormone levels
directly or effects on a biomarker (see } 22.a) or an endpoint
(for example an effect on behaviour, fecundity, growth,
disease resistance or survival). The results will be
influenced by duration and mode of exposure (for
example whether in the animal’s diet or environment),
and by the sex and development stage of the animals
used. Chronic effects of long-term exposure are more
difficult to study compared with acute effects, and are
typically estimated using standardized short-term or
longer-term assays. Standardized multigenerational
assays have been developed for a very limited range of
species including species of small fish, rodents and
some invertebrates [B].a. Only a limited set of species can be maintained in the
laboratory (legally and logistically), and work on
many species of most concern (for example, endan-
gered species or large vertebrates) is typically
impossible. Even for those species that can be main-
tained in the laboratory it will not be possible to
measure all potentially relevant endpoints. Extrapol-
ation of results from laboratory to wildlife species
must therefore be made with caution. Logistic and
welfare considerations limit the number of animals
that can be used in an experiment, reducing the
statistical power to detect small effects [B].
b. Experiments using a range of exposure concentrations
are used to calculate ‘no observable adverse effect
levels’ (NOAEL) or ‘lowest observable adverse effect
levels’ (LOAEL), which are then used to define ‘safe’
thresholds. Non-linearities in the dose–response
relation and the difficulties of statistically estimating
weak effects may lead to these levels being either
over- or under-estimated [B].
c. Effects observed in the laboratory are often termed
‘environmentally relevant’ if they involve concen-
trations that have been recorded in the field. In using
such a term (or a similar expression), it is desirable
to distinguish between peak concentrations (for
example near a wastewater effluent site or at a particu-
lar time of year) and more typical concentrations in the
broader environment and over all seasons [E].
d. Non-monotonic dose responses (NMDRs) occur where
the harmful effect of an EDC increases (or decreases) at
both low and high concentrations. There are some lab-
oratory reports of NMDRs from in vitro experiments
and in vivo biomarkers [L]. However, further studies
are needed to confirm the reproducibility of these
observations, which would have implications for
testing strategies and risk assessment [E].
e. The adverse effects caused by chronic low-level
exposure (‘low-dose effects’)may not necessarily be pre-
dictable from the effects of higher test doses over shorter
exposure times. Current chronic ecotoxicity tests gener-
ally include lower concentrations than those used in the
past [E].
f. There is strong evidence for maternal transfer of some
EDCs to offspring via eggs in fish, amphibians, reptiles
and birds, or via milk or across the placenta in mam-
mals [S]. There is weaker evidence for other
transgenerational effects [L].
g. Wildlife species are exposed to complex mixtures of
chemicals. There is evidence that EDCs with similar
endocrine action combine additively to affect labora-
tory model animals [S], and those with opposing
effects (for example, masculinizing and feminizing
compounds) may counteract each other [E]. Overall,
knowledge of how EDCs interact with each other
and with other pollutants is limited [E].
i. For example, five steroid pharmaceuticals, each at
levels belowtheNOEAL, led toa reduction in thenum-
bers of eggs produced by fish when present together
(consistent with a model of independent action).
ii. Indices such as oestradiol equivalence for oestro-
genic compounds or the toxic equivalency factor
for PCBs and related compounds are used to




820. Statistical, physiological and population dynamic models
can be used to extrapolate laboratory data to estimate
individual and population harm [B].
a. Understanding how molecular and physiological
effects of EDCs observed in the laboratory relate to
individual harm in the field can be difficult. For
example, a dose that under relatively benign labora-
tory conditions causes minor harm may have a more
major effect in the wild where animals are subject to
other biological and non-biological stressors [E]. Con-
versely, laboratory tests may expose animals to
constant concentrations of a substance that they may
encounter intermittently in the field [E].
b. Wildlife populations may be exposed to highly variable
levels of EDCs, possibly restricted to certain life-
history stages, factors that complicate extrapolation of
laboratory data to the field [E].
c. Translating the harm done to individuals to effects on
population size and viability is hard as it requires
knowledge of the species’ ecology. For example, if
the size of a population is limited by food then the
deaths or reproductive failure of some individuals
may not cause significant population decline as the
survivors have more food. In contrast, if a population
is near a threshold size for viability (possibly because
of difficulties in finding mates) relatively few failures
to breed could cause extinction [E].
21. Direct measurements of some persistent EDCs can be
made in wildlife, and the potential harm they cause
inferred from laboratory experiments (typically on differ-
ent species). [B].
a. The presence of the compound per se does not necess-
arily indicate an adverse effect [L]. Some adverse
effects may only become apparent long after the com-
pound has dissipated [S] and early life exposure may
change sensitivities to other compounds in later life [L].
b. High and potentially harmful concentrations of highly
persistent EDCs such as PCBs (} 7.c) occur in the
tissue of some predatory birds and sea mammals due
to bioaccumulation and biomagnification (} 17) [S].
c. Determining the effect of individual substances in
mixtures of EDCs and other substances is difficult
(} 19.g) [E].
22. Observations in wildlife of hormone levels, biomarkers or
pathologies associated with endocrine disruption can
signal the presence of one or more endocrine-active
chemicals in the environment. The signal can suggest
the type of EDC involved but may not provide an
indication of the specific compound [L].
a. In this context, the term ‘biomarker’ refers to some-
thing that can be measured in an organism that
covaries with processes influenced by EDCs. While a
biomarker change is not an adverse effect, biomarkers
are valuable because they can provide an indication of
endocrine effects before the effects are strong enough
to adversely affect individual health or population via-
bility. However, biomarkers may be affected by other
factors in addition to EDCs and it can be difficult to
determine the relationship between these changes
and individual or population harm [E].
i. The most widely used biomarker in wildlife is the
egg-laying vertebrate egg protein precursor vitello-
genin. The presence of the protein (or transcriptionof the gene responsible) in males indicates exposure
to oestrogenic compounds [S].
b. Interference with the hormones involved in sexual
development and reproduction can result in a variety
of pathologies including feminization of males, mascu-
linization of females, intersexes (individuals showing
bothmale and female characters), changes inmating be-
haviour, sex ratio biases, poor sperm viability and
reproductive failure [S]. Compounds include TBT
(} 7.a), DDT (} 7.b), PCBs (} 7.c) and oestrogens (} 8).
c. Thyroid hormones are important in regulating the
basal metabolic rate and heart rate, and for growth
and development, particularly of the long bones and
brain. They are also important in the control of meta-
morphosis timing in amphibians [B]. Correlations
between thyroid hormone levels and different EDCs,
particularly some types of PCBs (} 7.c) and PBDEs
(} 11.d), have been reported in a variety of different
wildlife, and there is evidence of a correlation between
bone density and PCB exposure in mammals [L].
d. Instances of impaired immunity in wildlife have been
associated with endocrine active substances including
perfluorooctanoic acid (a PFAS) (} 11.c), TBT (} 7.a),
PCBs (} 7.c) and trenbolone (} 10.a), but the extent
and type of effects these chemicals have on immunity
in wildlife are poorly understood [L].
23. Concern about specific EDCs (e.g. DDT } 7.b, PCBs } 7.c)
has arisen because of observations of population declines
in wildlife followed by physiological and toxicological
studies that have demonstrated endocrine pathologies
or high concentrations of that compound. Because the
association is correlational rather than experimental,
establishing a causal link can be challenging [B].
a. EDCs may reduce population viability through nega-
tive effects on reproduction [S]. This may not be
quickly recognized in long-lived species as there is
little immediate effect on population size [B].
24. In principle, field experiments can be used to test the
effects of EDCs on wildlife populations, but these are
expensive and logistically difficult to carry out with
sufficient replication [B].
a. Researchers added the artificial oestrogen 17a-ethinyl
oestradiol (EE2), used in contraceptive pills (} 8) to a
lake in Canada. The resulting concentrations of EE2
varied during the year, and at their highest were
approximately an order of magnitude greater than the
concentrations found in typical effluents (though con-
centrations of all oestrogenic compounds may reach
these levels). Comparedwith two control lakes and pre-
vious population data, one species of fish (fathead
minnow) declined drastically in numbers, though the
responses of the other species were more variable [S].
(E) Major European and international chemical
legislation concerning endocrine disrupting
chemicals
This section briefly indicates some of the major international
legislation relevant to EDCs.
25. The Stockholm Convention on Persistent Organic Pollu-




9production, use and release of POPs. While many POPs are
EDCs, they are covered under the Stockholm Convention
due to their persistent and bioaccumulative properties
rather than because of endocrine disruption [B].
a. Chemicals are listed in three categories: Annex A, pro-
duction and use to be eliminated; Annex B, use
restricted; Annex C, production and unintentional
release to be reduced with the goal of elimination [B].
26. European Union legislation affecting EDCs differs in the
degree to which it takes a hazard-based (emphasizing
intrinsic endocrine disrupting properties) or risk-based
(emphasizing exposure in addition) approach. Plant Protec-
tion Products (such as pesticides) and Biocidal Products
legislation emphasize hazard while REACH legislation
(which treats EDCs as ‘substances of very high concern’)
emphasizes risk [B]. Under REACH, many substances,
includingEDCs,maybesubject to ‘riskmitigationmeasures’,
which reduce human exposure and environmental release.
While EDCs are assumed to have no safe threshold, plant
protection products that are EDCs may be used where
human exposure is negligible (‘cut-off criteria’) [B].
a. In addition to EU laws, countries in the Union are sub-
ject to a number of global and regional conventions
that apply to particular types of substance.
b. Other European legislation relevant to EDCs includes the
Water Framework Directive, which deals with pollution
of ground and surface water by substances including,
but not limited to, EDCs; the Environmental Quality
Standards Directive (which includes a ‘watchlist’ of
chemicals of potential concern) and the Cosmetics
Regulation that deals with personal care products con-
taining EDCs [B]. The Marine Strategy Framework
Directive deals with pollution of the marine environ-
ment; this includes the monitoring of both contaminant
concentrations and their biological effects.
c. Human pharmaceuticals are regulated separately and
are exempt from REACH legislation. An environmental
assessment of risks associated with their production
and consumption phase is required for products regis-
tered post-2004 (EU Directive 2004/27/EC) but
authorization cannot be denied on environmental
grounds [B].
d. The same type of compound can be treated differently
by multiple pieces of legislation, for example fungici-
dal azoles that are used in crop protection and
pharmaceuticals [B].
27. Trade in electronic waste and other hazardous materials
is governed by the UNEP Basel Convention on the Con-
trol of Transboundary Movements of Hazardous Wastes
and their Disposal. In addition, the Strategic Approach
to International Chemicals Management (SAICM) of the
UNEP and the WHO is a policy framework designed to
promote chemical safety globally [B].
(F) What can be done about endocrine
disrupting chemicals
This section explores the options open to policy-makers to
reduce the effects of EDCs on wildlife.
28. The production and use of some EDCs that pose threats
to wildlife have been banned or their use severelyrestricted (though often the primary motivation for a
ban is risk to human health) [B].
a. Banning (or restrictions on use) leads to a reduction in
environmental concentrations, though slowly in the
case of more persistent molecules (with PCBs [} 7.c]
being particularly problematic) [S].
b. There is evidence of the recovery of wildlife popula-
tions in the years (sometimes decades) following
chemical bans, e.g. TBT (} 7.a), DDT (} 7.b) and
PCBs (} 7.c).
29. Incentivizing replacements for EDCs by chemicals that
do not cause endocrine disruption, or are less potent
EDCs, can reduce threats to wildlife [E].
a. There are cases where proposed alternatives have sub-
sequently been shown also to be EDCs. For example,
PBDEs (} 11.d) were developed as a replacement for
PCBs (} 7.c) but were found to be persistent and bioac-
cumulating EDCs and subsequently some types were
banned. Other bromine-containing flame retardants
have been developed as replacements, and have also
been detected in wildlife, though without harm
being demonstrated [S]. Similarly, there is concern
that other bisphenol compounds used to replace
bisphenol A (} 11.a) are also EDCs, although effects
are only observed at concentrations higher than
those currently observed in the environment [L].
30. Wastewater treatment can substantially reduce the
amounts of pharmaceutical and other EDCs (as well as
other chemicals) entering the environment from this
source. Interventions include (but are not limited to) per-
colation through granular activated carbon, treatment
with ozone or wetland construction. Investment in waste-
water treatment is determined both by decisions in the
private sector and the regulatory environment put in
place by government [B].
a. It has been estimated that upgrading all wastewater
plants to granular activated carbon treatment with
the specific aim of removing EDCs would cost E30 bil-
lion in England and Wales [E]. There are other energy-
intensive tertiary treatments and augmented biologi-
cal treatments that effectively remove EDCs [L].
However, cost, performance and consistency vary,
and long-term evaluation is needed [B].
b. The more strategic placement of wastewater outlets
and management of water levels to reduce periods
of low flow could, in theory, reduce the effects of
EDCs by ensuring rapid dilution, but the costs and
local acceptability of new infrastructure frequently
make such changes infeasible [E].
31. Careful handling of waste and of material from industrial
and domestic demolition can reduce the volume of EDCs
entering the environment. For example, UK regulations
require that persistent organic pollutants are either
destroyed by incineration or chemical destruction, or
are permanently stored underground [B].
a. Much material containing EDCs, in particular PCBs
(} 7.c), PFASs (} 11.c), PBDEs (} 11.d) and other
flame retardants, ends up in landfill. Choice of
landfill sites and their management can reduce
leaching and aerosol transport of EDCs into the
environment [S].
b. Recycling facilities (e.g. for electronics and plastic




10[S]. The presence of EDCs in many products is
unknown as labelling their presence has not been
required [B].
c. Large quantities of waste products enter the environ-
ment due to inadequate waste collection and poor
waste processing, particularly in developing countries
[B]. The EDCs derived from plastics and electronic
waste are of particular concern [E].
32. Decontamination of persistent EDCs from heavily
polluted sites is possible, although complex and
expensive. It is most often carried out where there is a
risk to humans. There is a range of decontamination
methods suitable for different substances and substrates,
including incineration, bioremediation, chemical
methods [B].
a. The US EPA Superfund Program has supported the
remediation of almost 400 sites, many of which were
contaminated with EDCs. Clean-up often involves
removal of soil or sediment (by dredging in rivers or
harbours) then containment of polluted material.
Monitoring of remediated sites has shown improve-
ments in indices of ecological health [S].
33. Specific measures can be taken to reduce the load of
EDCs derived from human pharmaceuticals (} 9) in
sewage treatment plants [B].
a. Better assessment of possible endocrine-mediated
effects on non-human animals, monitoring of sales
and prescription data, and a better understanding of
their passage through the body and half-life in the
environment, can help predict problems to wildlife [E].
b. Pharmaceutical EDCs can enter the environment
through incorrect disposal which can be reduced by
drug take-back schemes (mandated in the European
Union) [E]. It has been estimated that 5–10% of pre-
scribed drugs are not used, and of this 12–27% are
disposed of in domestic drains [L].
c. There is research into ‘green’ products that have equal
therapeutic effectiveness but reduced persistence in
the environment or cause less harm to wildlife [B].
Environmental assessments of many products are
available and may be used in prescribing [E].
d. For hospital and healthcare facilities where pharma-
ceutical use is high, separating urine from other waste
and then treating by continuous electrodialysis followed
by ozone decontamination may be justified [E].
34. There is no feasible way to remove most EDCs comple-
tely from the environment, or from the bodies of
wildlife. Affected populations may thus benefit from
special measures to reduce other stressors (for example,
habitat destruction, disease, hunting or persecution) to
improve population viability [E].
35. Monitoring EDC levels in the environment and wildlife,
and the population density and reproductive success of
affected species, is important in assessing the effective-
ness of policy interventions, prioritizing compounds
for assessments of persistence, bioaccumulative ability
and toxicity (PBT), and providing early warnings
of emerging EDC problems. All wildlife populations
naturally fluctuate, so extended time series are
required to detect trends. Monitoring can be logistically
challenging for some of the most at risk environments
and species (for example, large Arctic carnivores or
cetaceans) [B].a. The UK water industry is carrying out a national
programme monitoring 70 different chemicals in
effluent and water bodies including some EDCs [B].
b. Long-term monitoring programmes have shown per-
sistent organic pollutants in air, water, human
tissues (blood and breast milk) and wildlife (raptors
and otters) have declined, indicating bans have been
effective. However, monitoring programmes do not
cover all EDCs of concern (e.g. PFASs } 11.c) [S].
c. Historical wildlife population data collected for other
purposes, and archived environmental and animal
samples, have been valuable in determining baselines
and reference values to help interpret future data [S].
(G) Future opportunities and challenges
This section explores factors affecting EDC policy that may
change in the future.
36. EDC release into the environment will be affected by
demographic and economic trends. Growing populations
will lead to greater releases even if per capita use or
consumption remains constant. Increasing wealth in
developing countries will lead to higher releases
associated with greater consumption [S].
37. Recent (and probably future) advances in analytical
chemistry will allow the detection of more chemicals at
lower concentrations than is possible at the moment,
and at a cost that will allow an expansion of chemical
monitoring [E].
a. Increases in the amount of data on low concentrations
of known or suspected EDCs in wildlife and the
environment will increase demands for research on
the effects of very low-level exposure on individuals
and populations [E].
38. Modern molecular biology techniques offer the pros-
pect of high-throughput screening of multiple
biomarkers. Interpreting the very large datasets that
result, and developing predictors of harm at the indi-
vidual and especially population level, is a substantial
challenge [E].
a. There are no in vivo tests available for some types of
endocrine disruption or in some species [B].
39. Substantial uncertainty exists, and will continue to exist,
about possible negative environmental effects of different
EDCs, and the degree to which these can be predicted in
advance of their introduction. The challenge to policy-
makers in designing regulatory regimes is to balance
these risks against the economic and other benefits of
employing the substance [E].
a. Modern environmental economics using concepts
such as ecosystem services and natural capital may
be helpful in formal cost–benefit analyses, though
any regulatory framework will inevitably involve pol-
itical value judgements [E].
40. Climate change is likely to have both positive and nega-
tive influences on the relationship between EDCs and
wildlife. Models do not completely agree on how
environmental concentrations will change, particularly
in the Arctic [E].
a. Higher average temperatures will increase the rate
of volatilization (evaporation) and degradation of
chemical pollutants including EDCs [L].
royalsocietypublishing.org/journal/rspb
Proc.R.Soc.B
11b. Reducedannualprecipitationmayoccur in someregions,
leading to lower flows and less dilution of wastewater,
which will increase concentrations of EDCs [L].
c. An increase in extreme rainfall events is expected. This
may affect the frequency of point-pollution episodes
from farmland and from sewer overflows into river
water [L].
d. Climate change may cause stress for some wildlife and
lessen their ability to withstand further stresses in the
form of EDCs [S].
e. Climate change may affect the feeding ecology and
thus the exposure of wildlife species; for example, ear-
lier break-up of sea-ice has led to polar bears feeding
on more heavily contaminated seal species [S].
f. EDCs deposited in Arctic and glacial ice may be
released upon melting [S].
41. Better healthcare, ageing populations and the rise in
obesity and related co-morbidities may increase thedischarge of pharmaceutical EDCs (} 9) into the environ-
ment (though in an ageing population of constant size,
e.g. East Asia, the release of EDCs associated with contra-
ceptives may decline).
a. Countering this, the introduction and spread of
‘green’ pharmaceuticals and personalized medicine,
nanotechnology and other technologies that enable
better drug targeting, and so a reduction in dose,
which will reduce EDC discharges [E].
42. Less developed and developing countries tend to
have weaker environmental protection mechanisms,
and there is typically less information about local EDC
concentrations. Volatilization and long-range transport
of EDCs from countries with weak regulations can have
global consequences. How economic development
and environmental protection proceed will determine
whether their net effect as sources of EDCs increases or
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